🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523515-11-00
Completed Phase I

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

2025-523515-11-00 · tracked via the Priya Life Science EU tracker
Sponsor
Denali Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
18/02/2026
Enrollment target
27
Sites
Netherlands

Condition studied

Early Alzheimer's Disease

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523515-11-00 on CTIS ↗ ← All trials in the EU